SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

This study is testing a new way to treat very young children with medulloblastoma, a type of brain tumor. By using treatments tailored to the specific biology of each child's tumor, doctors hope to provide the most effective care while reducing unnecessary side effects.

This trial is for children under the age of 5 who have been recently diagnosed with medulloblastoma. To join, a child must be able to start treatment shortly after their initial surgery, and the family must be able to provide consent.

Participants will receive a combination of standard treatments, such as surgery and chemotherapy, personalized to their specific diagnosis. Doctors will also provide extra support and educational resources to help families navigate the treatment process.

The study is currently recruiting patients and is taking place at hospitals in Palo Alto, California, and Tampa and Orlando, Florida. You can speak with your oncology team to see if one of these locations is right for your family.